ProKidney Corp (PROK) Touts Reparencel Therapy for Growth

ProKidney Corp (NASDAQ:PROK) is one of the best healthcare penny stocks to buy now. On September 8, at the Morgan Stanley 23rd Annual Global Healthcare Conference, the company reiterated its focus on the promising cell therapy, Reparencel. yezry/Shutterstock.com The company anticipates top-line results from the cell therapy currently in Phase 3 of the Proactive One study by the second quarter of 2027. Enrollment in the ProAct One study is 50% complete, with the company targeting high-risk patients with chronic kidney disease and a GFR of 30 or less. ProKidney remains in a solid financial position, with $295 million in cash as of June, which is sufficient to bring the clinical trial to fruition. It has also started strengthening its manufacturing capacity in North Carolina in anticipation of strong demand. ProKidney Corp (NASDAQ:PROK) is a clinical-stage biotechnology company that develops a first-in-class cell therapy, rilparencel (also known as REACT), for the treatment of Chronic Kidney Disease (CKD). Its proprietary autologous cellular treatment uses a patient’s own kidney cells to potentially preserve kidney function, slow progression, and delay or prevent the need for dialysis. While we acknowledge the potential of PROK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 11 Best AI Stocks to Buy Under $5 and 12 Best Beginner Stocks to Buy According to Analysts. Disclosure: None. This article is originally published at Insider Monkey.